Catalyst Pharmaceuticals

CPRXApproved

Catalyst Pharmaceuticals is a publicly traded biopharma company dedicated to improving the lives of patients with rare diseases through a combination of strategic acquisitions, in-licensing, and targeted development. The company has successfully commercialized therapies for neuromuscular conditions and maintains a pipeline focused on expanding indications and exploring new therapeutic areas. Its leadership team combines deep commercial and clinical expertise, driving a culture of urgency and empathy centered on patient needs.

Market Cap

$2.8B

Focus

Small Molecules

CPRX · Stock Price

USD 22.79+14.80 (+185.23%)

Historical price data

AI Company Overview

Technology Platform

Catalyst's platform is a commercial and development engine specialized for rare diseases, focusing on strategic asset acquisition, targeted lifecycle management, and robust patient support services, supplemented by an Investigator-Sponsored Research (ISR) strategy to explore new indications.

Pipeline Snapshot

14 drugs in pipeline, 6 in Phase 3

Drug	Indication	Stage
amifampridine phosphate + Placebo	Myasthenic Syndromes, Congenital	Phase 3
Amifampridine Phosphate	Myasthenia Gravis, MuSK	Phase 3
Amifampridine Phosphate + Placebo	Lambert Eaton Myasthenic Syndrome	Phase 3
Amifampridine Phosphate + Placebo Oral Tablet	Lambert-Eaton Myasthenic Syndrome	Phase 3
Amifampridine Phosphate + Placebo Oral Tablet	Myasthenia Gravis, Generalized	Phase 3

FDA Approved Drugs

AGAMREENDAOct 26, 2023

FIRDAPSENDANov 28, 2018

Opportunities

Significant opportunities exist in expanding the labels of AGAMREE® and FIRDAPSE® into adjacent rare diseases through Investigator-Sponsored Research.

Furthermore, Catalyst's strong cash flow and commercial platform position it to acquire or in-license additional late-stage or commercial rare disease assets, driving the next phase of growth.

Risk Factors

Key risks include reliance on two primary products for revenue, execution risk in business development (finding and integrating suitable new assets), ongoing regulatory and reimbursement challenges in the rare disease space, and potential competitive or legal threats to its marketed products.

Competitive Landscape

Catalyst competes with standard-of-care corticosteroids and other disease-modifying therapies in DMD (for AGAMREE®) and holds a dominant, approved position in LEMS (for FIRDAPSE®). As a rare disease commercializer, it also competes with larger biopharma firms for attractive acquisition targets, differentiating itself through its focused, agile, and patient-centric operational model.

Publications

Patents

Pipeline

FDA Approvals